Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Baxter
Merck
Mallinckrodt
McKesson

Last Updated: May 28, 2022

GELNIQUE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Gelnique patents expire, and when can generic versions of Gelnique launch?

Gelnique is a drug marketed by Allergan and is included in two NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-one patent family members in thirteen countries.

The generic ingredient in GELNIQUE is oxybutynin. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxybutynin profile page.

DrugPatentWatch® Generic Entry Outlook for Gelnique

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for GELNIQUE
Drug patent expirations by year for GELNIQUE
Drug Prices for GELNIQUE

See drug prices for GELNIQUE

Drug Sales Revenue Trends for GELNIQUE

See drug sales revenues for GELNIQUE

Recent Clinical Trials for GELNIQUE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 3
Academic and Community Cancer Research UnitedPhase 3
University of Colorado, DenverN/A

See all GELNIQUE clinical trials

Pharmacology for GELNIQUE
Paragraph IV (Patent) Challenges for GELNIQUE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
GELNIQUE Gel oxybutynin chloride 10% 022204 1 2014-06-19

US Patents and Regulatory Information for GELNIQUE

GELNIQUE is protected by three US patents.

Patents protecting GELNIQUE

Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL

Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN

Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204-001 Jan 27, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Allergan GELNIQUE 3% oxybutynin GEL, METERED;TRANSDERMAL 202513-001 Dec 7, 2011 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Allergan GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204-001 Jan 27, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Allergan GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204-001 Jan 27, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for GELNIQUE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204-001 Jan 27, 2009 See Plans and Pricing See Plans and Pricing
Allergan GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204-001 Jan 27, 2009 See Plans and Pricing See Plans and Pricing
Allergan GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204-001 Jan 27, 2009 See Plans and Pricing See Plans and Pricing
Allergan GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204-001 Jan 27, 2009 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for GELNIQUE

See the table below for patents covering GELNIQUE around the world.

Country Patent Number Title Estimated Expiration
Mexico 2011011642 UN PROCEDIMIENTO PARA TRATAR VEJIGAS HIPERACTIVAS Y UN DISPOSITIVO PARA ALMACENAMIENTO Y ADMINISTRACION DE COMPOSICIONES TOPICAS DE OXIBUTININA. (A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS.) See Plans and Pricing
Brazil 0110381 Minimizando experiência adversa associada com terapia com oxibutinina See Plans and Pricing
Canada 2504021 COMPOSITIONS ET PROCEDES DESTINES A LA THERAPIE PAR OXYBUTYNINE TRANSDERMIQUE (COMPOSITIONS AND METHODS FOR TRANSDERMAL OXYBUTYNIN THERAPY) See Plans and Pricing
World Intellectual Property Organization (WIPO) 2010129498 See Plans and Pricing
Japan 2017008085 オキシブチニン治療に関連した有害な経験の最小化 (MINIMIZING ADVERSE EXPERIENCE ASSOCIATED WITH OXYBUTYNIN THERAPY) See Plans and Pricing
European Patent Office 1992342 Minimisation d'expérience indésirable associée à la thérapie oxybutynine (Minimizing adverse experience associated with oxybutynin therapy) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Medtronic
Colorcon
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.